Clinical Trial Update: CAR T Cells After Lymphodepletion for the Treatment of IL13Rα2 Positive Recurrent or Refractory Brain Tumors in Children [Phase 1]

View source ↗

Summary

A Phase 1 trial is evaluating IL13Rα2-targeted CAR T cells after lymphodepletion for pediatric patients with IL13Rα2-positive recurrent or refractory brain tumo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Brain Neoplasm

Drugs mentioned

• IL13Rα2-targeted CAR T cells

Snippet

Sponsor: City of Hope Medical Center | Conditions: Malignant Brain Neoplasm, Recurrent Malignant Brain Neoplasm | Phase 1 | Status: RECRUITING